Evidence map›Paper›PMID 30923755›Full record

ArticleParasite epidemiology and control2019

Target Product Profile for a point-of-care diagnostic test for dermal leishmaniases.

Israel Cruz, Audrey Albertini, Mady Barbeitas, Byron Arana, Albert Picado, Jose A Ruiz-Postigo, Joseph M Ndung'u

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Parasite epidemiology and control, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 5 pooled it
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 5 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Israel CruzFoundation for Innovative New Diagnostics, Geneva, Switzerland.
Audrey AlbertiniFoundation for Innovative New Diagnostics, Geneva, Switzerland.
Mady BarbeitasDrugs for Neglected Diseases Initiative - Latin America, Rio de Janeiro, Brazil.
Byron AranaDrugs for Neglected Diseases Initiative, Geneva, Switzerland.
Albert PicadoFoundation for Innovative New Diagnostics, Geneva, Switzerland.
Jose A Ruiz-PostigoWorld Health Organization, Department of Neglected Tropical Diseases, Geneva, Switzerland.
Joseph M Ndung'uFoundation for Innovative New Diagnostics, Geneva, Switzerland.
Foundation for Innovative New Diagnostics · CHDrugs for Neglected Diseases Initiative · CHWorld Health Organization · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

objectivesLocalized cutaneous leishmaniasis and its evolving forms diffuse cutaneous leishmaniasis, mucosal leishmaniasis and cutaneous leishmaniasis recidivans, together with the visceral leishmaniasis sequelae post-kala azar dermal leishmaniasis account for about one million dermal leishmaniases cases per year worldwide. Although not lethal, the dermal leishmaniases cause chronic and disfiguring skin lesions, which are an important cause of morbidity and stigma.Microscopy remains the reference test for diagnosis of dermal leishmaniasis; however, it has low and variable sensitivity and requires well trained personnel. The technical complexity and cost of the more sensitive molecular techniques (e.g. PCR) limits their application in routine diagnosis in endemic areas. Point-of-care (POC) tests for early diagnosis are much needed in order to benefit both patients and communities, by reducing the risk of both sequelae and

methodsThe TPP was defined through several rounds of discussions and by consensus with stakeholders and experts in dermal leishmaniases from different type of organizations and endemic regions. RESULTS AND

conclusionsA rapid, simple and robust test that can be implemented in resource-limited settings, enabling decentralized diagnosis and treatment of dermal leishmaniasis should be developed. Ideally it should enable the diagnosis of all forms of dermal leishmaniasis, but the minimally accepted target would be localized cutaneous leishmaniasis. A minimum sensitivity of 95% and specificity of 90% would be required. The consensus was that the POC test should target

Indexed as

Cutaneous leishmaniasisDermal leishmaniasisLeishmaniasisPoint-of-care diagnosticsTarget Product Profile

Identifiers

PMID30923755
PMCPMC6423987
OpenAlexW2921141173

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.